Corrigendum

Corrigendum to Ostrom et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015, Neuro-Oncology, Volume 20, Issue suppl_4,(doi.org/10.1093/neuonc/noy131) first published online October, 01 2018.

The authors of the abovementioned article wish to correct inaccuracies in multiple tables. The data listed under Nerve Sheath Tumors were reversed in the Malignant and non-Malignant rows in the following tables: Tables 3, 4, 10 and 11. In addition, data listed for multiple states were incorrect in Tables 8 and 9. These revised tables are included here with all changes marked in yellow highlight. All of these tables (unhighlighted) have now been updated with correct information and have been modified in the freely available online version of this publication.

Table 3.

Five-Year Total, Annual Average Total^a, and Average Annual Age-Adjusted Incidence Rates^b with 95% Confidence Intervals for Brain and Other Central Nervous System Tumors by Major Histology Grouping, Histology, Behavior, and Sex, CBTRUS Statistical Report: NPCR and SEER, 2011–2015

Histology	Total						Male						Female
	5 year total	Annual average	% of All Tumors	Median Age	Rate	95% CI	5 year total	Annual average	% Malignant	% Non- Malignant	Rate	95% CI	5 year total	Annual average	% Malignant	% Non- Malignant	Rate	95% CI
Tumors of Neuroepithelial Tissue	110,861	22,172	28.2%	57	6.57	6.53–6.61	62,126	12,425	93.0%	7.0%	7.70	7.64–7.76	48,735	9747	92.3%	7.7%	5.57	5.52–5.62
Pilocytic astrocytoma	5212	1042	1.3%	12	0.35	0.34–0.36	2701	540	100.0%	0.0%	0.36	0.35–0.37	2511	502	100.0%	0.0%	0.35	0.33–0.36
Diffuse astrocytoma	7562	1512	1.9%	48	0.46	0.45–0.48	4193	839	100.0%	0.0%	0.53	0.51–0.55	3369	674	100.0%	0.0%	0.40	0.39–0.42
Anaplastic astrocytoma	6797	1359	1.7%	53	0.41	0.40–0.42	3712	742	100.0%	0.0%	0.46	0.45–0.48	3085	617	100.0%	0.0%	0.36	0.34–0.37
Unique astrocytoma variants	1161	232	0.3%	23	0.08	0.07–0.08	631	126	68.5%	31.5%	0.08	0.08–0.09	530	106	67.5%	32.5%	0.07	0.06–0.07
Malignant	790	158	--	31	0.05	0.05-0.05	432	86	--	--	0.06	0.05–0.06	358	72	--	--	0.04	0.04–0.05
Non-Malignant	371	74	--	11	0.03	0.02–0.03	199	40	--	--	0.03	0.02–0.03	172	34	--	--	0.02	0.02–0.03
Glioblastoma	57,805	11,561	14.7%	65	3.21	3.18–3.23	33,348	6670	100.0%	0.0%	4.00	3.95–4.04	24,457	4891	100.0%	0.0%	2.53	2.50–2.56
Oligodendroglioma	3679	736	0.9%	43	0.23	0.23–0.24	2048	410	100.0%	0.0%	0.26	0.25–0.28	1631	326	100.0%	0.0%	0.20	0.19–0.21
Anaplastic oligodendroglioma	1767	353	0.4%	50	0.11	0.10–0.11	978	196	100.0%	0.0%	0.12	0.11–0.13	789	158	100.0%	0.0%	0.10	0.09–0.10
Oligoastrocytic tumors	2651	530	0.7%	42	0.17	0.16–0.17	1512	302	100.0%	0.0%	0.19	0.18–0.21	1139	228	100.0%	0.0%	0.14	0.13–0.15
Ependymal tumors	6858	1372	1.7%	44	0.43	0.42–0.44	3877	775	56.3%	43.7%	0.49	0.47–0.51	2981	596	62.5%	37.5%	0.37	0.36–0.38
Malignant	4045	809	--	42	0.25	0.25–0.26	2183	437	--	--	0.28	0.27–0.29	1862	372	--	--	0.23	0.22–0.25
Non-Malignant	2813	563	--	47	0.17	0.17–0.18	1694	339	--	--	0.21	0.20–0.22	1119	224	--	--	0.14	0.13–0.14
Glioma malignant, NOS	7518	1504	1.9%	36	0.48	0.47–0.49	3824	765	100.0%	0.0%	0.50	0.49–0.52	3694	739	100.0%	0.0%	0.46	0.44–0.47
Choroid plexus tumors	820	164	0.2%	20	0.05	0.05–0.06	411	82	16.5%	83.5%	0.05	0.05–0.06	409	82	14.9%	85.1%	0.05	0.05–0.06
Malignant	129	26	--	2	0.01	0.01-0.01	68	14	--	--	0.01	0.01-0.01	61	12	--	--	0.01	0.01-0.01
Non-Malignant	691	138	--	24	0.04	0.04–0.05	343	69	--	--	0.04	0.04–0.05	348	70	--	--	0.05	0.04–0.05
Other neuroepithelial tumors	100	20	0.0%	36	0.01	0.01-0.01	34	7	47.1%	52.9%	0.00	0.00–0.01	66	13	75.8%	24.2%	0.01	0.01-0.01
Malignant	66	13	--	25.5	0.00	0.00–0.01	16	3	--	--	0.00	0.00-0.00	50	10	--	--	0.01	0.00–0.01
Non-Malignant	34	7	--	41	0.00	0.00-0.00	18	4	--	--	0.00	0.00-0.00	16	3	--	--	0.00	0.00-0.00
Neuronal and mixed neuronal- glial tumors	4640	928	1.2%	26.5	0.30	0.29–0.31	2487	497	21.4%	78.6%	0.32	0.31–0.33	2153	431	18.1%	81.9%	0.28	0.27–0.29
Malignant	922	184	--	52	0.06	0.05–0.06	532	106	--	--	0.07	0.06–0.07	390	78	--	--	0.05	0.04–0.05
Non-Malignant	3718	744	--	22	0.24	0.24–0.25	1955	391	--	--	0.26	0.24–0.27	1763	353	--	--	0.23	0.22–0.24
Tumors of the pineal region	767	153	0.2%	35	0.05	0.05-0.05	307	61	68.1%	31.9%	0.04	0.04-0.04	460	92	46.3%	53.7%	0.06	0.05–0.06
Malignant	422	84	--	26.5	0.03	0.03-0.03	209	42	--	--	0.03	0.02–0.03	213	43	--	--	0.03	0.02–0.03
Non-Malignant	345	69	--	41	0.02	0.02-0.02	98	20	--	--	0.01	0.01–0.02	247	49	--	--	0.03	0.03-0.03
Embryonal tumors	3524	705	0.9%	8	0.24	0.23–0.25	2063	413	97.8%	2.2%	0.28	0.26–0.29	1461	292	95.8%	4.2%	0.20	0.19–0.21
Tumors of Cranial and Spinal Nerves	33,771	6754	8.6%	56	1.96	1.94–1.98	16,209	3242	0.7%	99.3%	1.96	1.93–1.99	17,562	3512	0.7%	99.3%	1.96	1.93–1.99
Nerve sheath tumors	33,738	6748	8.6%	56	1.96	1.94–1.98	16,187	3237	0.7%	99.3%	1.96	1.93–1.99	17,551	3510	0.7%	99.3%	1.96	1.93–1.99
Malignant	225	45	--	56	0.01	0.01–0.02	107	21	--	--	0.01	0.01–0.02	118	24	--	--	0.01	0.01–0.02
Non-Malignant	33,513	6703	--	52	1.94	1.92–1.96	16,080	3216	--	--	1.94	1.91–1.98	17,433	3487	--	--	1.95	1.92–1.98
Other tumors of cranial and spinal nerves	33	7	0.0%	50	0.00	0.00-0.00	22	4	0.0%	100.0%	0.00	0.00-0.00	--	--	0.0%	0.0%	--	--
Tumors of Meninges	150,390	30,078	38.3%	65	8.60	8.56–8.65	41,602	8320	2.8%	97.2%	5.26	5.21–5.31	108,788	21,758	1.3%	98.7%	11.54	11.47–11.61
Meningioma	145,916	29,183	37.1%	66	8.33	8.29–8.37	39,262	7852	1.9%	98.1%	4.97	4.92–5.02	106,654	21,331	1.0%	99.0%	11.28	11.21–11.35
Malignant	1771	354	--	65	0.10	0.10–0.11	751	150	--	--	0.09	0.09–0.10	1020	204	--	--	0.11	0.10–0.12
Non-Malignant	144,145	28,829	--	66	8.23	8.18–8.27	38,511	7702	--	--	4.88	4.83–4.93	105,634	21,127	--	--	11.18	11.11–11.24
Mesenchymal tumors	1385	277	0.4%	49	0.09	0.08–0.09	683	137	35.7%	64.3%	0.09	0.08–0.09	702	140	28.1%	71.9%	0.08	0.08–0.09
Primary melanocytic lesions	123	25	0.0%	58	0.01	0.01-0.01	72	14	100.0%	0.0%	0.01	0.01-0.01	51	10	51.0%	49.0%	0.01	0.00–0.01
Other neoplasms related to the meninges	2966	593	0.8%	49	0.18	0.17–0.19	1585	317	8.4%	91.6%	0.20	0.19–0.21	1381	276	9.0%	91.0%	0.16	0.16–0.17
Lymphomas and Hematopoietic Neoplasms	7818	1564	2.0%	66	0.45	0.44–0.46	4032	806	100.0%	0.0%	0.50	0.48–0.51	3786	757	100.0%	0.0%	0.40	0.39–0.41
Lymphoma	7585	1517	1.9%	66	0.43	0.42–0.44	3900	780	100.0%	0.0%	0.48	0.47–0.50	3685	737	100.0%	0.0%	0.39	0.38–0.40
Other hematopoietic neoplasms	233	47	0.1%	50	0.01	0.01–0.02	132	26	100.0%	0.0%	0.02	0.01–0.02	101	20	100.0%	0.0%	0.01	0.01-0.01
Germ Cell Tumors and Cysts	1487	297	0.4%	16	0.10	0.09–0.10	1017	203	77.2%	22.8%	0.13	0.13–0.14	470	94	46.6%	53.4%	0.06	0.06–0.07
Germ cell tumors, cysts and heterotopias	1487	297	0.4%	16	0.10	0.09–0.10	1017	203	77.2%	22.8%	0.13	0.13–0.14	470	94	46.6%	53.4%	0.06	0.06–0.07
Malignant	1004	201	--	15	0.07	0.06–0.07	785	157	--	--	0.10	0.10–0.11	219	44	--	--	0.03	0.03–0.04
Non-Malignant	483	97	--	28	0.03	0.03-0.03	232	46	--	--	0.03	0.03-0.03	251	50	--	--	0.03	0.03–0.04
Tumors of Sellar Region	67,765	13,553	17.2%	51	4.12	4.09–4.16	30,749	6150	0.4%	99.6%	3.81	3.77–3.86	37,016	7403	0.2%	99.8%	4.51	4.47–4.56
Tumors of the pituitary	64,749	12,950	16.5%	51	3.94	3.91–3.97	29,268	5854	0.4%	99.6%	3.63	3.58–3.67	35,481	7096	0.2%	99.8%	4.33	4.28–4.37
Malignant	175	35	--	57	0.01	0.01-0.01	103	21	--	--	0.01	0.01–0.02	72	14	--	--	0.01	0.01-0.01
Non-Malignant	64,574	12,915	--	51	3.93	3.89–3.96	29,165	5833	--	--	3.61	3.57–3.66	35,409	7082	--	--	4.32	4.27–4.36
Craniopharyngioma	3016	603	0.8%	43.5	0.19	0.18–0.20	1481	296	0.0%	100.0%	0.19	0.18–0.20	1535	307	0.0%	100.0%	0.19	0.18–0.20
Unclassified Tumors	20,890	4178	5.3%	63	1.23	1.22–1.25	9413	1883	34.3%	65.7%	1.22	1.19–1.24	11,477	2295	30.5%	69.5%	1.26	1.23–1.28
Hemangioma	6182	1236	1.6%	50	0.38	0.37–0.39	2646	529	0.0%	100.0%	0.33	0.32–0.34	3536	707	0.0%	100.0%	0.42	0.41–0.43
Neoplasm, unspecified	14,588	2918	3.7%	69	0.85	0.83–0.86	6698	1340	47.8%	52.2%	0.88	0.86–0.90	7890	1578	44.1%	55.9%	0.83	0.81–0.85
Malignant	6679	1336	--	76	0.38	0.37–0.39	3201	640	--	--	0.42	0.41–0.44	3478	696	--	--	0.35	0.33–0.36
Non-Malignant	7909	1582	--	63	0.47	0.46–0.48	3497	699	--	--	0.45	0.44–0.47	4412	882	--	--	0.48	0.47–0.50
All other	120	24	0.0%	65	0.01	0.01-0.01	69	14	0.0%	100.0%	0.01	0.01-0.01	51	10	31.4%	68.6%	0.01	0.00–0.01
TOTAL c	392,982	78,596	--	60	23.03	22.96–23.11	165,148	33,030	40.7%	59.3%	20.59	20.49–20.69	227,834	45,567	23.7%	76.3%	25.31	25.20–25.42
Malignant	121,277	24,255	30.9%	59	7.12	7.08–7.16	67,210	13,442	--	--	8.35	8.28–8.41	54,067	10,813	--	--	6.05	5.99–6.10
Non-Malignant	271,705	54,341	69.1%	60	15.91	15.85–15.97	97,938	19,588	--	--	12.25	12.17–12.32	173,767	34,753	--	--	19.26	19.17–19.36

aAnnual average cases are calculated by dividing the five-year total by five.

bRates are per 100,000 and are age-adjusted to the 2000 US standard population.

cRefers to all brain tumors including histologies not presented in this table.

-Counts are not presented when fewer than 16 cases were reported for the specific histology category.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results program; CI, confidence interval; NOS, not otherwise specified

Table 4.

Five-Year Total, Annual Average Total^a, and Average Annual Age-Adjusted Incidence Rates^b with 95% Confidence Intervals of Brain and Other Central Nervous System Tumors by Major Histology Grouping, Histology, and NCI Age Group, CBTRUS Statistical Report: NPCR and SEER, 2011–2015

Histology	Age at Diagnosis
	Childrenc (0–14)				AYAd (15–39)				Adults (40+)
	5 year total	Annual average	Rate	(95% CI)	5 year total	Annual average	Rate	(95% CI)	5 year total	Annual average	Rate	(95% CI)
Tumors of Neuroepithelial Tissue	12,573	2515	4.11	4.04–4.18	18,249	3650	3.48	3.43–3.53	80,039	16,008	10.35	10.27–10.42
Pilocytic astrocytoma	3096	619	1.01	0.98–1.05	1521	304	0.28	0.27–0.30	595	119	0.08	0.08–0.09
Diffuse astrocytoma	723	145	0.24	0.22–0.25	2272	454	0.43	0.41–0.45	4567	913	0.61	0.59–0.62
Anaplastic astrocytoma	291	58	0.10	0.08–0.11	1669	334	0.32	0.30–0.33	4837	967	0.64	0.62–0.66
Unique astrocytoma variants	386	77	0.13	0.11–0.14	413	83	0.08	0.07–0.08	362	72	0.05	0.04–0.05
Malignant	162	32	0.05	0.05–0.06	300	60	0.06	0.05–0.06	328	66	0.04	0.04–0.05
Non-Malignant	224	45	0.07	0.06–0.08	113	23	0.02	0.02-0.02	34	7	0.01	0.00–0.01
Glioblastoma	507	101	0.17	0.15–0.18	2662	532	0.53	0.51–0.55	54,636	10,927	6.93	6.87–6.99
Oligodendroglioma	100	20	0.03	0.03–0.04	1425	285	0.28	0.26–0.29	2154	431	0.30	0.29–0.31
Anaplastic oligodendroglioma	--	--	--	--	442	88	0.09	0.08–0.10	1314	263	0.18	0.17–0.19
Oligoastrocytic tumors	52	10	0.02	0.01–0.02	1138	228	0.22	0.21–0.23	1461	292	0.20	0.19–0.21
Ependymal tumors	977	195	0.32	0.30–0.34	1907	381	0.37	0.35–0.38	3974	795	0.53	0.52–0.55
Malignant	864	173	0.28	0.26–0.30	1028	206	0.20	0.18–0.21	2153	431	0.29	0.28–0.30
Non-Malignant	113	23	0.04	0.03–0.04	879	176	0.17	0.16–0.18	1821	364	0.24	0.23–0.26
Glioma malignant, NOS	2390	478	0.78	0.75–0.81	1565	313	0.30	0.28–0.31	3563	713	0.47	0.46–0.49
Choroid plexus tumors	352	70	0.11	0.10–0.13	218	44	0.04	0.04–0.05	250	50	0.03	0.03–0.04
Malignant	98	20	0.03	0.03–0.04	16	3	0.00	0.00-0.00	--	--	--	--
Non-Malignant	254	51	0.08	0.07–0.09	202	40	0.04	0.03–0.04	235	47	0.03	0.03–0.04
Other neuroepithelial tumors	25	5	0.01	0.01-0.01	31	6	0.01	0.00–0.01	44	9	0.01	0.00–0.01
Malignant	22	4	0.01	0.00–0.01	18	4	0.00	0.00–0.01	26	5	0.00	0.00–0.01
Non-Malignant	--	--	--	--	--	--	--	--	18	4	0.00	0.00-0.00
Neuronal and mixed neuronal-glial tumors	1204	241	0.39	0.37–0.42	1861	372	0.35	0.33–0.36	1575	315	0.21	0.20–0.23
Malignant	60	12	0.02	0.01–0.03	197	39	0.04	0.03–0.04	665	133	0.09	0.08–0.10
Non-Malignant	1144	229	0.37	0.35–0.40	1664	333	0.31	0.29–0.32	910	182	0.13	0.12–0.13
Tumors of the pineal region	154	31	0.05	0.04–0.06	283	57	0.05	0.05–0.06	330	66	0.05	0.04–0.05
Malignant	134	27	0.04	0.04–0.05	144	29	0.03	0.02–0.03	144	29	0.02	0.02-0.02
Non-Malignant	20	4	0.01	0.00–0.01	139	28	0.03	0.02–0.03	186	37	0.03	0.02–0.03
Embryonal tumors	2305	461	0.75	0.72–0.78	842	168	0.16	0.14–0.17	377	75	0.05	0.05–0.06
Medulloblastomae	1444	289	0.47	0.45–0.50	601	120	0.11	0.10–0.12	156	31	0.02	0.02–0.03
Primitive neuroectodermal tumorf	271	54	0.09	0.08–0.10	142	28	0.03	0.02–0.03	141	28	0.02	0.02-0.02
Atypical teratoid/rhabdoid tumorg	382	76	0.12	0.11–0.14	21	4	0.00	0.00–0.01	--	--	--	--
Other embryonal histologiesh	208	42	0.07	0.06–0.08	78	16	0.01	0.01–0.02	68	14	0.01	0.01-0.01
Tumors of Cranial and Spinal Nerves	861	172	0.28	0.26–0.30	5132	1026	1.01	0.98–1.04	27,778	5556	3.58	3.54–3.62
Nerve sheath tumors	861	172	0.28	0.26–0.30	5122	1024	1.01	0.98–1.03	27,755	5551	3.58	3.53–3.62
Malignant	17	3	0.01	0.00–0.01	49	10	0.01	0.01-0.01	159	32	0.02	0.02-0.02
Non-Malignant	844	169	0.28	0.26–0.30	5073	1015	1.00	0.97–1.02	27,596	5519	3.56	3.51–3.60
Other tumors of cranial and spinal nerves	--	--	--	--	--	--	--	--	23	5	0.00	0.00-0.00
Tumors of Meninges	554	111	0.18	0.17–0.20	10,280	2056	2.09	2.04–2.13	139,556	27,911	18.18	18.08–18.28
Meningioma	295	59	0.10	0.09–0.11	9003	1801	1.84	1.80–1.88	136,618	27,324	17.79	17.69–17.88
Malignant	19	4	0.01	0.00–0.01	131	26	0.03	0.02–0.03	1621	324	0.21	0.20–0.22
Non-Malignant	276	55	0.09	0.08–0.10	8872	1774	1.81	1.78–1.85	134,997	26,999	17.58	17.48–17.68
Mesenchymal tumors	185	37	0.06	0.05–0.07	325	65	0.06	0.06–0.07	875	175	0.12	0.11–0.12
Primary melanocytic lesions	--	--	--	--	--	--	--	--	101	20	0.01	0.01–0.02
Other neoplasms related to the meninges	67	13	0.02	0.02–0.03	937	187	0.18	0.17–0.19	1962	392	0.26	0.25–0.27
Lymphomas and Hematopoietic Neoplasms	75	15	0.02	0.02–0.03	555	111	0.11	0.10–0.12	7188	1438	0.94	0.91–0.96
Lymphoma	24	5	0.01	0.01-0.01	509	102	0.10	0.09–0.11	7052	1410	0.92	0.90–0.94
Other hematopoietic neoplasms	51	10	0.02	0.01–0.02	46	9	0.01	0.01-0.01	136	27	0.02	0.01–0.02
Germ Cell Tumors and Cysts	641	128	0.21	0.19–0.23	650	130	0.12	0.11–0.13	196	39	0.03	0.02–0.03
Germ cell tumors, cysts and heterotopias	641	128	0.21	0.19–0.23	650	130	0.12	0.11–0.13	196	39	0.03	0.02–0.03
Malignant	464	93	0.15	0.14–0.17	514	103	0.09	0.09–0.10	26	5	0.00	0.00–0.01
Non-Malignant	177	35	0.06	0.05–0.07	136	27	0.03	0.02–0.03	170	34	0.02	0.02–0.03
Tumors of Sellar Region	1572	314	0.52	0.49–0.54	19,632	3926	3.76	3.71–3.82	46,561	9312	6.22	6.17–6.28
Tumors of the pituitary	897	179	0.29	0.27–0.31	18,943	3789	3.63	3.58–3.68	44,909	8982	6.01	5.95–6.06
Malignant	--	--	--	--	26	5	0.01	0.00–0.01	149	30	0.02	0.02-0.02
Non-Malignant	897	179	0.29	0.27–0.31	18,917	3783	3.62	3.57–3.68	44,760	8952	5.99	5.93–6.04
Craniopharyngioma	675	135	0.22	0.21–0.24	689	138	0.13	0.12–0.14	1652	330	0.22	0.21–0.23
Unclassified Tumors	997	199	0.33	0.31–0.35	3323	665	0.64	0.62–0.66	16,570	3314	2.18	2.14–2.21
Hemangioma	362	72	0.12	0.11–0.13	1643	329	0.32	0.30–0.33	4177	835	0.56	0.54–0.57
Neoplasm, unspecified	613	123	0.20	0.18–0.22	1668	334	0.32	0.30–0.33	12,307	2461	1.61	1.58–1.64
Malignant	164	33	0.05	0.05–0.06	371	74	0.07	0.06–0.08	6144	1229	0.80	0.78–0.82
Non-Malignant	449	90	0.15	0.13–0.16	1297	259	0.25	0.23–0.26	6163	1233	0.81	0.79–0.83
All other	22	4	0.01	0.00–0.01	--	--	--	--	86	17	0.01	0.01-0.01
TOTAL i	17,273	3455	5.65	5.56–5.73	57,821	11,564	11.20	11.11–11.29	317,888	63,578	41.47	41.32–41.62
Malignant	11,624	2325	3.80	3.73–3.87	17,023	3405	3.26	3.21–3.31	92,630	18,526	11.97	11.89–12.04
Non-Malignant	5649	1130	1.85	1.80–1.90	40,798	8160	7.94	7.87–8.02	225,258	45,052	29.50	29.38–29.63

aAnnual average cases are calculated by dividing the five-year total by five.

bRates are per 100,000 and age-adjusted to the 2000 US standard population.

cChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.

dAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/cancertopics/aya.

eICD-O-3 histology codes: 9470/3, 9471/3, 9472/3, 9474/3.

fICD-O-3 histology code: 9473/3.

gICD-O-3 histology code: 9508/3.

hICD-O-3 histology codes: 8963/3, 9364/3, 9480/3, 9490/0, 9490/3, 9500/3, 9501/3, 9502/3.

iRefers to all brain tumors including histologies not presented in this table.

-Counts and rates are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts and rates for totals.

Abbreviations: AYA, Adolescents and Young Adults, CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results program; CI, confidence interval; NOS, not otherwise specified

Table 10.

Distribution of Histologically-Confirmed Brain and Other Central Nervous System Tumors by WHO Grade, Treatment Information Completeness and Major Histology Grouping, CBTRUS Statistical Report: NPCR and SEER, 2011–2015

Histology	Number of Newly Diagnosed Tumors (2011–2015)	Histologically Confirmed (%)	WHO Grade Completeness (%)			Assigned WHO Grade				Radiation Information Completenessb (%)	Surgical Extent of Resection Information Completenessc (%)
			Completea	Incomplete	Not Applicable	Grade I	Grade II	Grade III	Grade IV
Tumors of Neuroepithelial Tissue	110,861	89.3%	84.1%	14.4%	1.5%	10.7%	14.4%	13.7%	61.1%	49.1%	98.1%
Pilocytic astrocytoma	5212	91.9%	85.8%	13.9%	0.4%	92.8%	6.0%	0.8%	0.4%	6.0%	99.1%
Diffuse astrocytoma	7562	92.3%	84.7%	15.2%	0.1%	3.7%	61.5%	21.0%	13.8%	44.5%	98.0%
Anaplastic astrocytoma	6797	99.3%	94.2%	5.7%	0.1%	0.1%	1.2%	90.1%	8.6%	70.1%	99.3%
Unique astrocytoma variants	1161	76.3%	74.9%	24.8%	0.2%	22.9%	55.1%	16.9%	5.1%	18.2%	98.1%
Malignant	790	87.2%	77.1%	22.8%	0.1%	4.0%	68.5%	21.1%	6.4%	26.3%	98.0%
Non-Malignant	371	53.1%	67.5%	32.0%	0.5%	98.5%	1.5%	0.0%	0.0%	0.8%	98.4%
Glioblastoma	57,805	93.1%	86.8%	13.2%	0.0%	0.2%	0.2%	0.8%	98.8%	62.2%	97.9%
Oligodendroglioma	3679	96.4%	92.6%	7.4%	0.1%	1.5%	86.0%	6.8%	5.7%	25.7%	98.5%
Anaplastic oligodendroglioma	1767	99.2%	95.1%	4.9%	0.0%	0.1%	2.8%	88.4%	8.6%	62.8%	98.7%
Oligoastrocytic tumors	2651	99.5%	95.1%	4.9%	0.0%	0.8%	51.1%	39.9%	8.1%	49.6%	99.5%
Ependymal tumors	6858	90.1%	84.2%	15.8%	0.0%	35.3%	49.8%	14.1%	0.7%	23.7%	98.5%
Malignant	4045	94.0%	87.7%	12.3%	0.1%	2.7%	74.3%	22.0%	1.1%	34.3%	98.4%
Non-Malignant	2813	84.4%	78.5%	21.5%	0.0%	93.8%	6.0%	0.1%	0.1%	8.4%	98.6%
Glioma malignant, NOS	7518	32.6%	44.4%	54.7%	0.9%	20.7%	28.6%	24.2%	26.6%	23.8%	97.8%
Choroid plexus tumors	820	88.3%	73.6%	26.4%	0.0%	66.0%	17.1%	16.3%	0.6%	4.9%	98.1%
Malignant	129	97.7%	81.0%	19.0%	0.0%	7.8%	3.9%	85.3%	2.9%	18.6%	100.0%
Non-Malignant	691	86.5%	72.1%	27.9%	0.0%	79.8%	20.2%	0.0%	0.0%	2.3%	97.8%
Other neuroepithelial tumors	100	96.0%	46.9%	52.1%	1.0%	6.7%	53.3%	24.4%	15.6%	36.0%	100.0%
Malignant	66	100.0%	36.4%	62.1%	1.5%	4.2%	20.8%	45.8%	29.2%	47.0%	100.0%
Non-Malignant	34	88.2%	70.0%	30.0%	0.0%	9.5%	90.5%	0.0%	0.0%	14.7%	100.0%
Neuronal and mixed neuronal-glial tumors	4640	93.4%	61.7%	21.1%	17.2%	79.9%	15.6%	3.8%	0.8%	14.1%	98.6%
Malignant	922	98.6%	15.1%	5.6%	79.3%	19.7%	6.6%	62.8%	10.9%	54.2%	97.7%
Non-Malignant	3718	92.1%	74.1%	25.2%	0.7%	83.1%	16.0%	0.6%	0.2%	4.1%	98.8%
Tumors of the pineal region	767	75.7%	0.0%	0.0%	100.0%	--	--	--	--	35.9%	97.5%
Malignant	422	95.0%	0.0%	0.0%	100.0%	--	--	--	--	56.4%	99.1%
Non-Malignant	345	52.2%	0.0%	0.0%	100.0%	--	--	--	--	10.7%	96.3%
Embryonal tumors	3524	98.1%	73.2%	25.9%	0.9%	1.2%	0.2%	1.5%	97.1%	56.7%	97.5%
Tumors of Cranial and Spinal Nerves	33,771	51.2%	31.0%	69.0%	0.0%	99.0%	0.5%	0.3%	0.2%	17.1%	98.3%
Nerve sheath tumors	33,738	51.2%	31.0%	69.0%	0.0%	99.0%	0.5%	0.3%	0.2%	17.1%	98.3%
Malignant	225	82.7%	18.8%	81.2%	0.0%	48.6%	11.4%	28.6%	11.4%	32.4%	81.7%
Non-Malignant	33,513	51.0%	31.2%	68.8%	0.0%	99.3%	0.4%	0.1%	0.1%	17.0%	98.4%
Other tumors of cranial and spinal nerves	33	39.4%	30.8%	69.2%	0.0%	100.0%	0.0%	0.0%	0.0%	3.0%	100.0%
Tumors of Meninges	150,390	42.5%	75.5%	24.4%	0.1%	80.4%	17.4%	2.1%	0.1%	6.8%	97.9%
Meningioma	145,916	41.2%	77.1%	22.9%	0.0%	80.6%	17.6%	1.7%	0.1%	6.5%	97.9%
Malignant	1771	79.2%	82.9%	17.1%	0.0%	23.0%	16.1%	59.7%	1.2%	30.3%	85.1%
Non-Malignant	144,145	40.8%	77.0%	23.0%	0.0%	82.1%	17.6%	0.2%	0.1%	6.3%	98.0%
Mesenchymal tumors	1385	71.8%	49.9%	48.9%	1.1%	6.4%	50.7%	38.4%	4.4%	27.1%	98.4%
Primary melanocytic lesions	123	91.1%	10.7%	86.6%	2.7%	66.7%	16.7%	8.3%	8.3%	36.6%	94.2%
Other neoplasms related to the meninges	2966	91.7%	51.9%	46.7%	1.4%	99.2%	0.6%	0.1%	0.2%	6.8%	98.7%
Lymphomas and Hematopoietic Neoplasms	7818	94.0%	10.6%	87.7%	1.7%	100.0%	0.0%	0.0%	0.0%	21.4%	99.1%
Lymphoma	7585	94.1%	11.1%	88.0%	0.9%	100.0%	0.0%	0.0%	0.0%	21.1%	99.1%
Other hematopoietic neoplasms	233	90.6%	0.7%	82.1%	17.2%	100.0%	0.0%	0.0%	0.0%	31.8%	99.2%
Germ Cell Tumors and Cysts	1487	81.9%	1.8%	55.6%	42.6%	18.2%	9.1%	4.5%	68.2%	43.1%	99.0%
Germ cell tumors, cysts and heterotopias	1487	81.9%	1.8%	55.6%	42.6%	18.2%	9.1%	4.5%	68.2%	43.1%	99.0%
Malignant	1004	88.7%	2.1%	43.1%	54.7%	5.3%	10.5%	5.3%	78.9%	62.8%	99.1%
Non-Malignant	483	67.7%	0.9%	89.6%	9.5%	100.0%	0.0%	0.0%	0.0%	2.1%	98.9%
Tumors of Sellar Region	67,765	50.0%	0.5%	0.6%	98.9%	99.4%	0.0%	0.6%	0.0%	3.1%	98.0%
Tumors of the pituitary	64,749	48.4%	0.0%	0.0%	100.0%	100.0%	0.0%	0.0%	0.0%	2.3%	98.0%
Malignant	175	66.3%	0.0%	0.0%	100.0%	--	--	--	--	16.6%	88.2%
Non-Malignant	64,574	48.4%	0.0%	0.0%	100.0%	100.0%	0.0%	0.0%	0.0%	2.3%	98.0%
Craniopharyngioma	3016	83.9%	6.1%	8.6%	85.3%	99.4%	0.0%	0.6%	0.0%	20.2%	98.1%
Unclassified Tumors	20,890	17.5%	4.3%	87.1%	8.6%	64.1%	7.7%	11.5%	16.7%	2.7%	71.1%
Hemangioma	6182	29.0%	2.5%	97.1%	0.4%	93.3%	2.2%	2.2%	2.2%	1.8%	98.1%
Neoplasm, unspecified	14,588	12.5%	5.8%	78.0%	16.2%	52.8%	10.4%	14.2%	22.6%	2.9%	61.1%
Malignant	6679	8.7%	8.1%	84.8%	7.1%	14.9%	10.6%	27.7%	46.8%	4.0%	43.7%
Non-Malignant	7909	15.7%	4.8%	74.8%	20.5%	83.1%	10.2%	3.4%	3.4%	2.0%	76.2%
All other	120	40.0%	10.4%	62.5%	27.1%	40.0%	0.0%	40.0%	20.0%	10.8%	91.7%
TOTAL c	392,982	57.6%	62.0%	21.8%	16.2%	39.0%	14.9%	9.1%	37.1%	19.2%	96.1%
Malignant	121,277	85.3%	81.0%	17.0%	2.0%	6.5%	14.5%	15.3%	63.7%	47.4%	92.7%
Non-Malignant	271,705	45.3%	46.8%	25.6%	27.6%	84.3%	15.3%	0.3%	0.1%	6.6%	97.2%

aCompleteness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer’s Collaborative Staging schema.

bRadiation is defined using a recoded variable based on NAACCR Item #1360 (http://datadictionary.naaccr.org/default.aspx?c=10#136). Completeness is defined as having a value other than “none” or “unknown.”

cSurgery is defined using a recoded variable based on NAACCR Item #1290 (http://datadictionary.naaccr.org/default.aspx?c=10#1290). Please see the SEER site-specific surgery codes for more information on coding for this variable (https://seer.cancer.gov/archive/tools/SEER2003.surg.prim.site.codes.pdf). Completeness is defined as having a value other than “unknown.”

-Percentages are not presented when category is not applicable.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results program; WHO, World Health Organization

Table 11.

Five-Year Total, Annual Average Total^a, and Average Annual Age-Adjusted Incidence Rates^b with 95% Confidence Intervals for Brain and Other Central Nervous System Tumors by Major Histology Grouping, Histology, and Race^c, CBTRUS Statistical Report: NPCR and SEER, 2011–2015

Histology	White				Black				American Indian/Alaskan Native				Asian/Pacific Islander
	5 year total	Annual average	Rate	95% CI	5 year total	Annual average	Rate	95% CI	5 year total	Annual average	Rate	95% CI	5 year total	Annual average	Rate	95% CI
Tumors of Neuroepithelial Tissue	97,396	19,479	7.10	7.05–7.14	8321	1664	3.98	3.89–4.07	625	125	3.20	2.93–3.48	3664	733	4.07	3.93–4.20
Pilocytic astrocytoma	4260	852	0.38	0.37–0.39	603	121	0.26	0.24–0.28	40	8	0.15	0.11–0.21	257	51	0.29	0.26–0.33
Diffuse astrocytoma	6612	1322	0.51	0.50–0.52	578	116	0.27	0.25–0.30	53	11	0.26	0.19–0.34	261	52	0.28	0.25–0.32
Anaplastic astrocytoma	6028	1206	0.45	0.44–0.46	446	89	0.22	0.20–0.24	44	9	0.21	0.15–0.29	218	44	0.24	0.21–0.27
Unique astrocytoma variants	915	183	0.08	0.07–0.08	152	30	0.07	0.06–0.08	-	-	-	-	68	14	0.08	0.06–0.10
Malignant	646	129	0.05	0.05–0.06	81	16	0.04	0.03–0.05	-	-	-	-	44	9	0.05	0.04–0.07
Non-Malignant	269	54	0.02	0.02–0.03	71	14	0.03	0.02–0.04	-	-	-	-	24	5	0.03	0.02–0.04
Glioblastoma	52,306	10,461	3.47	3.44–3.50	3552	710	1.80	1.73–1.86	227	45	1.43	1.24–1.65	1365	273	1.57	1.48–1.66
Oligodendroglioma	3230	646	0.26	0.25–0.27	237	47	0.11	0.10–0.13	26	5	0.11	0.07–0.17	147	29	0.15	0.13–0.18
Anaplastic oligodendroglioma	1546	309	0.12	0.11–0.12	103	21	0.05	0.04–0.06	-	-	-	-	94	19	0.10	0.08–0.12
Oligoastrocytic tumors	2349	470	0.19	0.18–0.20	149	30	0.07	0.06–0.08	17	3	0.08	0.04–0.13	108	22	0.11	0.09–0.13
Ependymal tumors	5908	1182	0.47	0.45–0.48	540	108	0.25	0.23–0.27	59	12	0.27	0.20–0.35	297	59	0.31	0.28–0.35
Malignant	3419	684	0.27	0.26–0.28	367	73	0.17	0.15–0.19	33	7	0.14	0.10–0.21	192	38	0.21	0.18–0.24
Non-Malignant	2489	498	0.19	0.19–0.20	173	35	0.08	0.07–0.10	26	5	0.13	0.08–0.19	105	21	0.11	0.09–0.13
Glioma malignant, NOS	6234	1247	0.50	0.48–0.51	838	168	0.40	0.37–0.42	53	11	0.24	0.18–0.32	327	65	0.37	0.33–0.41
Choroid plexus tumors	680	136	0.06	0.05–0.06	87	17	0.04	0.03–0.05	-	-	-	-	37	7	0.04	0.03–0.06
Malignant	99	20	0.01	0.01-0.01	16	3	0.01	0.00–0.01	-	-	-	-	-	-	-	-
Non-Malignant	581	116	0.05	0.04–0.05	71	14	0.03	0.02–0.04	-	-	-	-	27	5	0.03	0.02–0.04
Other neuroepithelial tumors	84	17	0.01	0.01-0.01	-	-	-	-	-	-	-	-	-	-	-	-
Malignant	54	11	0.00	0.00–0.01	-	-	-	-	-	-	-	-	-	-	-	-
Non-Malignant	30	6	0.00	0.00-0.00	-	-	-	-	-	-	-	-	-	-	-	-
Neuronal and mixed neuronal-glial tumors	3814	763	0.32	0.31–0.33	498	100	0.22	0.20–0.24	38	8	0.17	0.12–0.23	244	49	0.26	0.23–0.30
Malignant	768	154	0.06	0.05–0.06	75	15	0.04	0.03–0.05	-	-	-	-	56	11	0.06	0.05–0.08
Non-Malignant	3046	609	0.26	0.25–0.27	423	85	0.18	0.17–0.20	27	5	0.11	0.07–0.17	188	38	0.20	0.17–0.23
Tumors of the pineal region	603	121	0.05	0.05-0.05	119	24	0.05	0.04–0.06	-	-	-	-	35	7	0.04	0.03–0.05
Malignant	308	62	0.03	0.02–0.03	81	16	0.04	0.03–0.04	-	-	-	-	24	5	0.03	0.02–0.04
Non-Malignant	295	59	0.02	0.02–0.03	38	8	0.02	0.01–0.02	-	-	-	-	-	-	-	-
Embryonal tumors	2827	565	0.25	0.24–0.26	411	82	0.17	0.16–0.19	36	7	0.14	0.10–0.20	201	40	0.23	0.20–0.26
Tumors of Cranial and Spinal Nerves	28,908	5782	2.06	2.04–2.09	2053	411	0.99	0.95–1.04	212	42	1.09	0.94–1.25	2233	447	2.36	2.26–2.46
Nerve sheath tumors	28,881	5776	2.06	2.04–2.08	2051	410	0.99	0.95–1.03	211	42	1.08	0.93–1.25	2230	446	2.36	2.26–2.46
Malignant	174	35	0.01	0.01–0.02	2025	405	0.98	0.93–1.02	209	42	1.07	0.92–1.24	2212	442	2.34	2.24–2.44
Non-Malignant	28,707	5741	2.05	2.02–2.07	26	5	0.01	0.01–0.02	-	-	-	-	18	4	0.02	0.01–0.03
Other tumors of cranial and spinal nerves	27	5	0.00	0.00-0.00	-	-	-	-	-	-	-	-	-	-	-	-
Tumors of Meninges	122,895	24,579	8.42	8.37–8.47	18,567	3713	9.91	9.77–10.06	875	175	5.44	5.06–5.84	7110	1422	8.39	8.19–8.59
Meningioma	119,167	23,833	8.14	8.09–8.18	18,135	3627	9.71	9.56–9.86	844	169	5.30	4.92–5.69	6859	1372	8.13	7.93–8.33
Malignant	1405	281	0.10	0.09–0.10	268	54	0.15	0.13–0.16	-	-	-	-	83	17	0.10	0.08–0.12
Non-Malignant	117,762	23,552	8.04	7.99–8.09	17,867	3573	9.56	9.42–9.71	836	167	5.24	4.87–5.64	6776	1355	8.02	7.83–8.22
Mesenchymal tumors	1167	233	0.09	0.08–0.10	123	25	0.06	0.05–0.07	-	-	-	-	80	16	0.09	0.07–0.11
Primary melanocytic lesions	112	22	0.01	0.01-0.01	-	-	-	-	-	-	-	-	-	-	-	-
Other neoplasms related to the meninges	2449	490	0.19	0.18–0.19	304	61	0.14	0.13–0.16	23	5	0.11	0.07–0.16	166	33	0.17	0.15–0.20
Lymphomas and Hematopoietic Neoplasms	6618	1324	0.45	0.44–0.46	645	129	0.32	0.30–0.35	49	10	0.27	0.20–0.37	437	87	0.51	0.46–0.56
Lymphoma	6422	1284	0.44	0.42–0.45	622	124	0.31	0.29–0.34	47	9	0.27	0.19–0.36	427	85	0.50	0.45–0.55
Other hematopoietic neoplasms	196	39	0.01	0.01–0.02	23	5	0.01	0.01–0.02	-	-	-	-	-	-	-	-
Germ Cell Tumors and Cysts	1179	236	0.10	0.10–0.11	146	29	0.06	0.05–0.07	-	-	-	-	141	28	0.16	0.13–0.19
Germ cell tumors, cysts and heterotopias	1179	236	0.10	0.10–0.11	146	29	0.06	0.05–0.07	-	-	-	-	141	28	0.16	0.13–0.19
Malignant	783	157	0.07	0.06–0.07	96	19	0.04	0.03–0.05	-	-	-	-	107	21	0.12	0.10–0.15
Non-Malignant	396	79	0.03	0.03–0.04	50	10	0.02	0.02–0.03	-	-	-	-	34	7	0.04	0.03–0.05
Tumors of Sellar Region	49,486	9897	3.76	3.73–3.80	13,009	2602	6.48	6.37–6.60	602	120	3.13	2.87–3.40	4119	824	4.39	4.26–4.53
Tumors of the pituitary	47,305	9461	3.59	3.56–3.62	12,392	2478	6.19	6.08–6.31	584	117	3.03	2.78–3.31	3948	790	4.21	4.07–4.34
Malignant	128	26	0.01	0.01-0.01	35	7	0.02	0.01–0.03	-	-	-	-	-	-	-	-
Non-Malignant	47,177	9435	3.58	3.55–3.61	12,357	2471	6.17	6.06–6.29	581	116	3.02	2.77–3.29	3939	788	4.20	4.06–4.33
Craniopharyngioma	2181	436	0.17	0.16–0.18	617	123	0.29	0.27–0.31	18	4	0.09	0.05–0.15	171	34	0.18	0.16–0.22
Unclassified Tumors	17,563	3513	1.26	1.24–1.27	2174	435	1.14	1.09–1.19	188	38	1.10	0.94–1.28	873	175	1.02	0.95–1.09
Hemangioma	5183	1037	0.39	0.38–0.41	569	114	0.27	0.25–0.30	75	15	0.38	0.30–0.48	325	65	0.35	0.31–0.39
Neoplasm, unspecified	12,296	2459	0.85	0.84–0.87	1579	316	0.85	0.81–0.90	111	22	0.70	0.57–0.86	541	108	0.67	0.61–0.73
Malignant	5814	1163	0.39	0.38–0.40	570	114	0.32	0.30–0.35	50	10	0.32	0.23–0.42	221	44	0.28	0.25–0.32
Non-Malignant	6482	1296	0.47	0.45–0.48	1009	202	0.53	0.50–0.56	61	12	0.39	0.29–0.51	320	64	0.38	0.34–0.43
All other	84	17	0.01	0.00–0.01	26	5	0.01	0.01–0.02	-	-	-	-	-	-	-	-
TOTAL d	324,045	64,809	23.15	23.07–23.23	44,915	8983	22.89	22.67–23.11	2561	512	14.27	13.68–14.87	18,577	3715	20.90	20.59–21.21
Malignant	106,225	21,245	7.62	7.57–7.67	9237	1847	4.52	4.42–4.61	682	136	3.62	3.33–3.92	4225	845	4.78	4.63–4.93
Non-Malignant	217,820	43,564	15.53	15.47–15.60	35,678	7136	18.37	18.17–18.57	1879	376	10.65	10.14–11.18	14,352	2870	16.12	15.85–16.39

aAnnual average cases are calculated by dividing the five-year total by five.

bRates are per 100,000 and are age-adjusted to the 2000 US standard population.

cIndividuals with unknown race were excluded (N = 2884).

dRefers to all brain tumors including histologies not presented in this table.

-Counts and rates are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts and rates for totals.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results program; CI, confidence interval; NOS, not otherwise specified

Table 8.

Characteristics of All Brain and Other Central Nervous System Tumors by Central Cancer Registry and Behavior, CBTRUS Statistical Report: NPCR and SEER, 2011–2015

State	Total				Malignant				Non-Malignant				Average Annual 2011–2015 Population
	5-Year Total	Annual Average	Histologically Confirmed (%)	Radio-graphically Confirmed (%)	5-Year Total	% Malignant	Histologically Confirmed (%)	Radio-graphically Confirmed (%)	5-Year Total	% Non-Malignant	Histologically Confirmed (%)	Radio-graphically Confirmed (%)
Alabama	4632	926	68.0%	27.3%	1854	40.0%	84.0%	6.2%	2778	60.0%	57.3%	41.4%	24,142,446
Alaska	809	162	49.8%	47.2%	227	28.1%	81.5%	12.8%	582	71.9%	37.5%	60.7%	3,665,095
Arizona	7584	1517	61.0%	33.4%	2475	32.6%	82.4%	8.2%	5109	67.4%	50.7%	45.7%	33,178,972
Arkansas	3275	655	58.0%	37.2%	1214	37.1%	79.4%	12.4%	2061	62.9%	45.4%	51.8%	14,793,606
California	42,410	8482	61.0%	34.7%	13,007	30.7%	86.3%	8.8%	29,403	69.3%	49.8%	46.2%	191,697,888
Colorado	7280	1456	49.5%	47.6%	1912	26.3%	82.0%	12.3%	5368	73.7%	38.0%	60.2%	26,374,297
Connecticut	4430	886	68.3%	29.8%	1513	34.2%	88.9%	8.9%	2917	65.9%	57.6%	40.6%	17,956,294
Delaware	1010	202	68.5%	28.5%	357	35.4%	84.3%	10.6%	653	64.7%	59.9%	38.3%	4,629,336
District of Columbia	717	143	61.6%	35.4%	192	26.8%	89.1%	5.7%	525	73.2%	51.6%	46.3%	3,234,351
Florida	28,326	5665	54.5%	42.3%	8164	28.8%	85.8%	9.9%	20,162	71.2%	41.7%	55.4%	98,156,785
Georgia	12,381	2476	52.8%	43.2%	3377	27.3%	85.3%	11.0%	9004	72.7%	40.7%	55.2%	49,997,845
Hawaii	1398	280	55.4%	36.6%	358	25.6%	86.0%	7.5%	1040	74.4%	44.9%	46.6%	7,017,671
Idaho	1813	363	64.8%	31.8%	658	36.3%	84.2%	11.7%	1155	63.7%	53.8%	43.2%	8,078,425
Illinois	16,388	3278	58.2%	39.8%	4821	29.4%	88.1%	8.6%	11,567	70.6%	45.7%	52.7%	64,316,906
Indiana	7836	1567	53.9%	42.9%	2536	32.4%	84.6%	11.9%	5300	67.6%	39.2%	57.7%	32,831,326
Iowa	4342	868	57.5%	40.2%	1379	31.8%	85.8%	11.2%	2963	68.2%	44.3%	53.6%	15,463,490
Kansas	3459	692	56.8%	39.9%	1180	34.1%	85.8%	10.0%	2279	65.9%	41.8%	55.4%	14,453,667
Kentucky	6816	1363	48.6%	47.0%	1956	28.7%	80.3%	13.1%	4860	71.3%	35.8%	60.7%	21,992,298
Louisiana	5554	1111	59.5%	36.0%	1605	28.9%	85.8%	10.0%	3949	71.1%	48.8%	46.6%	23,122,075
Maine	1528	306	65.1%	32.1%	642	42.0%	84.9%	11.1%	886	58.0%	50.8%	47.3%	6,646,374
Maryland	6452	1290	66.1%	29.8%	2122	32.9%	87.1%	6.7%	4330	67.1%	55.8%	41.2%	29,626,661
Massachusetts	7280	1456	71.1%	26.3%	2767	38.0%	88.4%	7.9%	4513	62.0%	60.5%	37.5%	33,510,868
Michigan	11,590	2318	60.4%	35.8%	3897	33.6%	85.0%	9.0%	7693	66.4%	47.9%	49.4%	49,495,915
Minnesota	5916	1183	76.0%	19.8%	2289	38.7%	90.2%	5.8%	3627	61.3%	67.1%	28.7%	27,082,912
Mississippi	3349	670	61.1%	35.5%	1063	31.7%	85.0%	11.1%	2286	68.3%	49.9%	46.8%	14,935,379
Missouri	7750	1550	55.3%	41.0%	2407	31.1%	87.5%	7.9%	5343	68.9%	40.8%	55.9%	30,215,977
Montana	1283	257	56.0%	40.5%	460	35.9%	84.1%	12.0%	823	64.2%	40.2%	56.5%	5,072,271
Nebraska	2025	405	60.3%	36.4%	768	37.9%	84.8%	9.8%	1257	62.1%	45.3%	52.7%	9,341,477
Nevada	2414	483	62.4%	31.9%	948	39.3%	83.3%	6.5%	1466	60.7%	48.8%	48.3%	11,255,800
New Hampshire	1612	322	67.9%	30.4%	596	37.0%	90.9%	6.5%	1016	63.0%	54.4%	44.4%	6,621,196
New Jersey	11,915	2383	58.5%	36.8%	3673	30.8%	87.6%	9.3%	8242	69.2%	45.5%	49.0%	44,474,038
New Mexico	2171	434	63.8%	30.1%	665	30.6%	86.9%	7.4%	1506	69.4%	53.6%	40.1%	10,410,085
New York	28,549	5710	53.7%	43.7%	7735	27.1%	86.2%	11.6%	20,814	72.9%	41.7%	55.7%	98,261,542
North Carolina	12,533	2507	57.8%	38.8%	3711	29.6%	85.0%	10.4%	8822	70.4%	46.4%	50.7%	49,208,313
North Dakota	733	147	55.7%	41.6%	268	36.6%	85.8%	10.8%	465	63.4%	38.3%	59.4%	3,608,321
Ohio	13,251	2650	64.8%	31.1%	4726	35.7%	84.6%	8.4%	8525	64.3%	53.9%	43.7%	57,865,183
Oklahoma	4510	902	51.9%	44.5%	1464	32.5%	80.2%	11.9%	3046	67.5%	38.2%	60.1%	19,240,656
Oregon	4498	900	68.3%	27.8%	1747	38.8%	85.1%	7.2%	2751	61.2%	57.7%	40.9%	19,685,903
Pennsylvania	19,135	3827	53.3%	43.1%	5721	29.9%	83.3%	10.6%	13,414	70.1%	40.5%	56.9%	63,879,954
Rhode Island	1133	227	68.1%	29.6%	422	37.3%	90.0%	6.6%	711	62.8%	55.1%	43.2%	5,268,472
South Carolina	6107	1221	53.6%	40.5%	1849	30.3%	84.5%	9.2%	4258	69.7%	40.1%	54.1%	23,884,555
South Dakota	1013	203	54.0%	42.8%	354	35.0%	83.6%	12.4%	659	65.1%	38.1%	59.2%	4,214,241
Tennessee	8709	1742	54.4%	43.4%	2473	28.4%	86.9%	9.9%	6236	71.6%	41.5%	56.7%	32,486,480
Texas	31,394	6279	51.6%	42.0%	9112	29.0%	80.9%	13.2%	22,282	71.0%	39.7%	53.8%	132,565,959
Utah	4175	835	54.8%	44.1%	994	23.8%	85.7%	12.7%	3181	76.2%	45.1%	53.9%	14,507,037
Vermont	877	175	57.6%	40.9%	260	29.7%	93.5%	6.2%	617	70.4%	42.5%	55.6%	3,133,386
Virginia	8350	1670	65.7%	30.5%	2872	34.4%	85.9%	6.8%	5478	65.6%	55.1%	42.8%	41,249,734
Washington	11,170	2234	50.1%	46.9%	2987	26.7%	85.2%	11.2%	8183	73.3%	37.3%	59.9%	34,900,238
West Virginia	2226	445	60.0%	37.2%	790	35.5%	88.6%	8.2%	1436	64.5%	44.2%	53.2%	9,254,330
Wisconsin	8222	1644	53.4%	43.6%	2482	30.2%	85.3%	11.0%	5740	69.8%	39.6%	57.6%	28,704,939
Wyoming	652	130	66.1%	33.1%	228	35.0%	86.8%	11.8%	424	65.0%	55.0%	44.6%	2,897,371
TOTAL	392,982	78,596	57.6%	38.6%	121,277	30.9%	85.3%	9.8%	271,705	69.1%	45.3%	51.4%	1,578,608,340

aPopulation estimates were obtained from the United States Bureau of the Census available on the SEER program website.

-Counts are not presented when fewer than 16 cases were reported for the specific category. The suppressed cases are included in the counts and rates for totals.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program

Table 9.

Average Annual Age-Adjusted Incidence Rates^a with 95% Confidence Intervals for Brain and Other Central Nervous System Tumors by Age, Behavior, and Central Cancer Registry, CBTRUS Statistical Report: NPCR and SEER, 2011–2015

	0–19 Years						20+ Years						All Ages
State	Malignant		Non-Malignant		All Tumors		Malignant		Non-Malignant		All Tumors		Malignant		Non-Malignant		All Tumors
	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
Alabama	3.31	2.88–3.80	1.27	1.00–1.58	4.58	4.06–5.15	8.40	7.99–8.83	13.95	13.41–14.50	22.35	21.67–23.04	6.94	6.62–7.27	10.31	9.92–10.71	17.25	16.75–17.77
Alaska	2.35	1.52–3.48	3.73	2.64–5.12	6.08	4.67–7.79	8.31	7.12–9.64	22.47	20.48–24.60	30.78	28.44–33.25	6.60	5.71–7.58	17.09	15.63–18.65	23.69	21.97–25.51
Arizona	3.13	2.78–3.52	2.47	2.16–2.82	5.61	5.13–6.12	8.27	7.92–8.63	18.87	18.33–19.42	27.14	26.49–27.79	6.79	6.52–7.07	14.17	13.77–14.57	20.96	20.48–21.45
Arkansas	3.59	3.03–4.23	2.34	1.88–2.87	5.93	5.19–6.74	8.93	8.39–9.49	16.85	16.09–17.63	25.78	24.84–26.73	7.40	6.98–7.84	12.69	12.13–13.26	20.08	19.38–20.80
California	3.03	2.88–3.19	2.10	1.98–2.23	5.13	4.94–5.33	8.05	7.90–8.21	20.16	19.92–20.40	28.21	27.93–28.50	6.61	6.50–6.73	14.98	14.81–15.15	21.59	21.38–21.80
Colorado	3.39	2.97–3.85	2.07	1.74–2.44	5.46	4.92–6.04	8.56	8.14–8.99	27.17	26.42–27.94	35.73	34.87–36.60	7.08	6.76–7.41	19.97	19.43–20.52	27.05	26.41–27.69
Connecticut	3.49	2.96–4.10	2.59	2.15–3.10	6.08	5.38–6.85	9.15	8.65–9.66	19.38	18.65–20.14	28.53	27.64–29.44	7.53	7.14–7.93	14.57	14.02–15.12	22.09	21.42–22.77
Delaware	4.10	3.01–5.45	2.79	1.91–3.94	6.88	5.45–8.58	7.99	7.10–8.96	16.52	15.21–17.92	24.51	22.92–26.20	6.87	6.16–7.65	12.58	11.61–13.62	19.46	18.24–20.74
District of Columbia	3.91	2.52–5.79	3.25	1.91–5.13	7.16	5.16–9.67	7.03	5.97–8.22	22.43	20.46–24.52	29.45	27.21–31.83	6.13	5.27–7.10	16.93	15.46–18.49	23.06	21.35–24.88
Florida	3.46	3.22–3.71	2.90	2.69–3.13	6.36	6.04–6.70	8.43	8.24–8.64	22.51	22.19–22.84	30.95	30.56–31.33	7.01	6.85–7.17	16.89	16.65–17.13	23.89	23.61–24.19
Georgia	3.47	3.16–3.79	2.44	2.19–2.72	5.91	5.51–6.33	8.02	7.72–8.32	24.24	23.72–24.77	32.26	31.67–32.87	6.71	6.49–6.95	17.99	17.61–18.37	24.70	24.26–25.15
Hawaii	1.99	1.37–2.78	1.56	1.02–2.28	3.54	2.70–4.56	5.56	4.95–6.22	17.71	16.60–18.87	23.27	21.99–24.59	4.53	4.06–5.05	13.08	12.27–13.93	17.61	16.67–18.59
Idaho	3.52	2.81–4.36	1.50	1.04–2.08	5.02	4.16–6.01	9.40	8.62–10.22	18.69	17.59–19.85	28.09	26.74–29.50	7.71	7.12–8.34	13.76	12.96–14.60	21.47	20.47–22.51
Illinois	3.31	3.04–3.60	2.52	2.28–2.77	5.83	5.47–6.20	8.58	8.32–8.85	22.72	22.30–23.16	31.31	30.80–31.81	7.07	6.87–7.28	16.93	16.61–17.24	24.00	23.62–24.37
Indiana	3.56	3.17–3.97	2.46	2.15–2.81	6.02	5.52–6.55	8.74	8.38–9.12	20.20	19.63–20.77	28.94	28.26–29.63	7.25	6.97–7.55	15.11	14.70–15.53	22.36	21.86–22.88
Iowa	3.91	3.33–4.56	3.52	2.97–4.14	7.43	6.62–8.31	9.61	9.06–10.18	22.71	21.85–23.60	32.32	31.29–33.36	7.97	7.54–8.42	17.20	16.57–17.86	25.18	24.41–25.96
Kansas	3.69	3.12–4.33	2.47	2.01–3.01	6.16	5.42–6.98	9.18	8.61–9.77	19.96	19.11–20.84	29.14	28.12–30.19	7.60	7.16–8.06	14.95	14.32–15.59	22.55	21.79–23.33
Kentucky	4.24	3.72–4.81	3.27	2.82–3.78	7.51	6.82–8.26	9.77	9.30–10.25	27.11	26.32–27.92	36.88	35.96–37.82	8.18	7.82–8.56	20.27	19.69–20.86	28.45	27.77–29.15
Louisiana	3.79	3.33–4.31	2.46	2.08–2.88	6.25	5.65–6.91	7.72	7.31–8.15	21.81	21.11–22.54	29.54	28.72–30.37	6.60	6.27–6.93	16.26	15.75–16.79	22.86	22.25–23.48
Maine	3.76	2.84–4.88	1.48	0.94–2.23	5.24	4.14–6.53	9.77	8.95–10.64	14.87	13.84–15.95	24.64	23.32–26.01	8.04	7.40–8.73	11.03	10.27–11.82	19.07	18.08–20.11
Maryland	3.40	3.00–3.84	1.41	1.16–1.71	4.81	4.33–5.33	8.08	7.71–8.47	18.35	17.79–18.92	26.43	25.75–27.12	6.74	6.45–7.04	13.49	13.08–13.91	20.23	19.73–20.74
Massachusetts	3.71	3.29–4.16	2.22	1.91–2.57	5.92	5.40–6.48	9.01	8.65–9.39	15.82	15.34–16.31	24.83	24.23–25.44	7.49	7.21–7.78	11.92	11.56–12.28	19.41	18.95–19.87
Michigan	3.44	3.12–3.78	1.86	1.63–2.11	5.30	4.91–5.72	8.52	8.23–8.82	18.69	18.26–19.14	27.22	26.69–27.75	7.06	6.84–7.30	13.86	13.55–14.19	20.93	20.54–21.33
Minnesota	3.99	3.54–4.48	2.04	1.73–2.40	6.04	5.48–6.63	9.51	9.09–9.95	16.43	15.87–17.00	25.94	25.24–26.65	7.93	7.60–8.27	12.30	11.90–12.72	20.23	19.70–20.76
Mississippi	3.03	2.52–3.61	2.45	1.99–2.98	5.48	4.79–6.24	8.16	7.63–8.71	19.27	18.45–20.12	27.43	26.45–28.43	6.69	6.28–7.11	14.45	13.85–15.06	21.13	20.41–21.88
Missouri	3.85	3.43–4.31	2.09	1.79–2.44	5.95	5.42–6.51	8.56	8.19–8.95	21.60	21.00–22.21	30.17	29.46–30.88	7.21	6.92–7.51	16.01	15.57–16.45	23.22	22.69–23.75
Montana	2.30	1.54–3.31	1.49	0.90–2.33	3.79	2.80–5.03	9.96	9.00–10.99	19.29	17.92–20.74	29.25	27.57–31.00	7.76	7.04–8.54	14.19	13.19–15.24	21.95	20.71–23.24
Nebraska	4.11	3.36–4.96	3.31	2.65–4.09	7.41	6.40–8.54	9.13	8.43–9.87	16.47	15.52–17.47	25.60	24.41–26.84	7.69	7.14–8.27	12.70	11.99–13.44	20.39	19.49–21.32
Nevadab	2.71	2.20–3.30	1.40	1.03–1.85	4.11	3.47–4.82	7.78	7.26–8.34	13.29	12.59–14.02	21.07	20.19–21.98	6.33	5.92–6.75	9.88	9.37–10.41	16.21	15.55–16.88
New Hampshire	4.76	3.72–6.00	2.36	1.68–3.24	7.12	5.85–8.59	9.20	8.41–10.06	17.80	16.66–19.00	27.01	25.61–28.47	7.93	7.28–8.62	13.37	12.53–14.26	21.30	20.24–22.41
New Jersey	3.62	3.27–3.99	2.85	2.55–3.18	6.47	6.01–6.96	9.17	8.85–9.49	22.41	21.90–22.92	31.57	30.98–32.18	7.57	7.33–7.83	16.80	16.43–17.17	24.37	23.93–24.82
New Mexico	2.60	2.03–3.26	1.60	1.17–2.14	4.20	3.47–5.03	7.05	6.48–7.66	18.05	17.11–19.03	25.10	24.00–26.25	5.77	5.33–6.24	13.33	12.65–14.05	19.11	18.29–19.95
New York	3.96	3.71–4.22	3.67	3.44–3.92	7.64	7.29–8.00	8.63	8.42–8.84	25.66	25.30–26.03	34.29	33.87–34.71	7.29	7.12–7.46	19.35	19.08–19.62	26.64	26.33–26.96
North Carolina	3.36	3.05–3.70	2.23	1.98–2.51	5.59	5.19–6.02	8.42	8.13–8.72	22.27	21.79–22.75	30.69	30.12–31.26	6.97	6.74–7.20	16.52	16.17–16.88	23.49	23.07–23.91
North Dakota	2.55	1.65–3.78	2.53	1.61–3.77	5.08	3.75–6.73	8.52	7.45–9.70	16.23	14.70–17.88	24.75	22.87–26.75	6.81	6.00–7.70	12.30	11.17–13.51	19.11	17.70–20.59
Ohio	3.91	3.60–4.24	2.55	2.30–2.82	6.46	6.06–6.89	8.74	8.46–9.01	17.52	17.13–17.92	26.26	25.78–26.74	7.35	7.14–7.57	13.23	12.94–13.52	20.58	20.22–20.94
Oklahoma	3.37	2.90–3.91	2.12	1.74–2.55	5.49	4.88–6.16	8.52	8.05–9.01	19.96	19.23–20.72	28.48	27.61–29.37	7.04	6.68–7.42	14.84	14.31–15.39	21.89	21.24–22.55
Oregon	3.94	3.39–4.54	2.73	2.29–3.24	6.67	5.96–7.44	9.53	9.05–10.03	16.48	15.83–17.14	26.01	25.20–26.84	7.93	7.55–8.32	12.53	12.06–13.03	20.46	19.85–21.09
Pennsylvania	4.11	3.80–4.45	2.39	2.16–2.65	6.51	6.11–6.92	9.29	9.02–9.55	24.30	23.87–24.74	33.59	33.09–34.10	7.80	7.59–8.01	18.02	17.70–18.34	25.82	25.44–26.20
Rhode Island	2.78	1.92–3.91	1.70	1.07–2.58	4.49	3.38–5.84	8.83	7.94–9.78	15.84	14.65–17.12	24.67	23.17–26.24	7.09	6.41–7.83	11.79	10.91–12.72	18.88	17.76–20.06
South Carolina	3.18	2.75–3.66	2.20	1.84–2.60	5.38	4.81–5.99	8.44	8.03–8.87	21.52	20.84–22.20	29.95	29.16–30.76	6.93	6.61–7.26	15.97	15.48–16.48	22.90	22.32–23.50
South Dakota	3.30	2.35–4.52	1.53	0.90–2.42	4.83	3.65–6.26	9.31	8.27–10.44	19.71	18.16–21.36	29.02	27.14–30.99	7.58	6.79–8.45	14.49	13.37–15.69	22.08	20.69–23.53
Tennessee	3.64	3.24–4.07	2.74	2.40–3.12	6.38	5.85–6.95	8.28	7.92–8.64	23.48	22.88–24.09	31.76	31.06–32.47	6.95	6.67–7.23	17.53	17.09–17.98	24.48	23.95–25.01
Texas	3.63	3.45–3.83	2.49	2.33–2.65	6.12	5.88–6.37	8.36	8.17–8.55	23.58	23.26–23.91	31.94	31.57–32.32	7.00	6.86–7.15	17.53	17.30–17.77	24.53	24.26–24.81
Utah	3.00	2.53–3.52	2.86	2.40–3.39	5.86	5.19–6.58	9.50	8.85–10.17	34.26	33.03–35.53	43.76	42.37–45.18	7.63	7.15–8.13	25.25	24.37–26.17	32.88	31.87–33.92
Vermont	--	--	3.33	2.14–4.93	5.51	3.92–7.52	9.05	7.90–10.32	22.80	20.92–24.81	31.85	29.63–34.20	7.08	6.21–8.05	17.21	15.82–18.70	24.29	22.64–26.04
Virginia	3.03	2.71–3.38	1.74	1.50–2.01	4.77	4.36–5.21	7.99	7.68–8.31	16.62	16.16–17.08	24.61	24.06–25.17	6.57	6.33–6.82	12.35	12.02–12.69	18.92	18.51–19.34
Washington	4.17	3.76–4.62	3.37	3.00–3.78	7.54	6.98–8.14	9.55	9.18–9.93	29.41	28.75–30.08	38.96	38.20–39.73	8.01	7.72–8.31	21.94	21.46–22.43	29.95	29.38–30.52
West Virginia	3.59	2.84–4.49	2.11	1.54–2.82	5.70	4.74–6.81	8.73	8.07–9.42	17.55	16.60–18.54	26.27	25.12–27.47	7.25	6.73–7.80	13.12	12.42–13.85	20.37	19.50–21.28
Wisconsin	3.69	3.26–4.16	2.52	2.17–2.91	6.21	5.65–6.80	9.46	9.06–9.88	24.26	23.61–24.92	33.72	32.95–34.50	7.81	7.49–8.13	18.02	17.55–18.51	25.83	25.26–26.41
Wyoming	2.07	1.18–3.37	--	--	3.29	2.13–4.85	9.49	8.21–10.91	18.95	17.11–20.93	28.44	26.18–30.84	7.36	6.40–8.42	13.86	12.53–15.30	21.22	19.57–22.98
TOTAL	3.51	3.45–3.56	2.44	2.39–2.49	5.94	5.87–6.02	8.57	8.52–8.63	21.33	21.25–21.42	29.91	29.81–30.01	7.12	7.08–7.16	15.91	15.85–15.97	23.03	22.96–23.11

aRates are per 100,000 and are age-adjusted to the 2000 US standard population.

bFor Nevada only, data was not available from 2011.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results program; CI, confidence interval